Displaying 1 publication

Abstract:
Sort:
  1. Fulltext Effectiveness and safety of early versus late caffeine therapy in managing apnoea of prematurity among preterm infants: a retrospective cohort study
    Yun WZ, Kassab YW, Yao LM, Khairuddin N, Ming LC, Hadi MA
    Int J Clin Pharm, 2022 Oct;44(5):1140-1148.
    PMID: 35915341 DOI: 10.1007/s11096-022-01437-0
    BACKGROUND: Early administration of intravenous (IV) caffeine (initiation within 2 days of life) is an effective treatment strategy for the management of apnoea of prematurity among infants. However, the safety and effectiveness of early administration of oral caffeine treatment is not be fully established.

    AIM: We aimed to compare the effectiveness and safety of early versus late caffeine therapy on preterm infants' clinical outcomes.

    METHOD: A retrospective matched cohort study was conducted using data of patients admitted to neonatal intensive care units of two tertiary care hospitals between January 2016 and December 2018. The clinical outcomes and mortality risk between early caffeine (initiation within 2 days of life) and late caffeine (initiation ≥ 3 days of life) were compared.

    RESULTS: Ninety-five pairs matched based on gestational age were included in the study. Compared to late initiation, preterm infants with early caffeine therapy had: a shorter duration of non-invasive mechanical ventilation (median 5 days vs. 12 days; p 

    Matched MeSH terms: Apnea/epidemiology
Related Terms
    Try searching for something
Filters
Contact Us

Please provide feedback to Administrator ([email protected])

External Links